{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The amount of GSK2816126 excreted in urine after dosing at steady state was planned to be determined. The concentration of GSK2816126 in urine was planned to be measured with an investigational bio-analytical method and extrapolated to total amount excreted in urine over time using urine volume. This analysis was planned but not performed for Part 2 as the study was terminated early during Part 1.","groups":[{"description":"Participants with GCB-DLBCL-mutant and wild type, TFL-mutant and wild type as well as participants with MM were planned to be enrolled in Part 2 of the study. Participants enrolled in Part 2 were planned to receive RP2D .","id":"OG000","title":"Part 2: All Participants"}],"populationDescription":"Pharmacokinetic Population. Data was not collected in Part2 as no participant was enrolled in Part2.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 0 to 24 hours post-dose on Day 1; 0 to 8 hours post-dose on Day 15","title":"Part 2:Concentration of GSK2816126 in Urine After Dosing at Steady State","type":"SECONDARY"}